AI Summary
ChromaDex's Q3 2024 sales hit $25.6 million, a 31% yearly increase. Niagen® ingredient sales soared 368% YoY, reflecting strong product demand. The company achieved a record net income of $1.9 million for Q3 2024. ChromaDex expanded its Niagen+ availability to over 100 clinics nationwide. FDA discussions initiated for Investigational New Drug application for NR.
Sentiment Rationale
Strong sales growth and profitability are positive indicators for CDXC.
Trading Thesis
Immediate market reactions expected due to quarterly results announcement.
Market-Moving
- ChromaDex's Q3 2024 sales hit $25.6 million, a 31% yearly increase.
- Niagen® ingredient sales soared 368% YoY, reflecting strong product demand.
- The company achieved a record net income of $1.9 million for Q3 2024.
Key Facts
- ChromaDex's Q3 2024 sales hit $25.6 million, a 31% yearly increase.
- Niagen® ingredient sales soared 368% YoY, reflecting strong product demand.
- The company achieved a record net income of $1.9 million for Q3 2024.
- ChromaDex expanded its Niagen+ availability to over 100 clinics nationwide.
- FDA discussions initiated for Investigational New Drug application for NR.
Companies Mentioned
- CDXC (CDXC)
- NRC (NRC)
Earnings
Robust financial performance directly impacts investor confidence and stock price.